- Home
- BMMX vs NRXP Comparison
BMMX vs NRXP Comparison
Compare BMMX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMMX | NRXP |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.0M | 151.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BMMX | NRXP |
|---|---|---|
| Price | $2.98 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.75 |
| AVG Volume (30 Days) | 28.2K | ★ 1.3M |
| Earning Date | 11-27-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $357.94 |
| Revenue Next Year | N/A | $1,281.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $1.65 |
| 52 Week High | $3.55 | $5.06 |
Technical Indicators
Market Signals| Indicator | BMMX | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 46.02 |
| Support Level | $2.50 | $1.68 |
| Resistance Level | $3.13 | $2.49 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 34.92 | 50.00 |
Price Performance
Historical ComparisonAbout BMMX Black Mammoth Metals Corporation Common Shares
Black Mammoth Metals Corp is a mineral exploration company. It is engaged in the acquisition and exploration of resource properties in Idaho and Nevada. Some of the properties of the company are Blanco Creek Property, Happy Cat Gold property, Quito Gold Property, America Mine Property, Amador Properties, Leadore Property, Adelaide Crown Property, and Others.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.